All Stories

  1. Clinical Reasoning: An Immunocompetent Young Adult With Acute Vision Loss
  2. Prelaminar optic neuritis in clinical practice: observations from five patients
  3. Parkinson's Disease and Retinal Age Gap: A Cross‐Sectional Analysis
  4. Corneal confocal microscopy as a paraclinical test in neurodegenerative disease: a scoping review
  5. Treatment of post-vaccination optic neuritis: implications from the global SARS-CoV-2 vaccination effort
  6. From anatomical and functional observations to molecular dynamics in internal limiting membrane peeling
  7. Proteolysis‐Based Biomarker Repertoire of the Neurofilament Proteome
  8. Methanol toxicity; characteristics, ophthalmological sequelae and recommended treatment
  9. Macular, choroidal and disc associations across women’s reproductive life stages: a scoping review from menarche to post-menopause
  10. Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children
  11. How far should I manage acute optic neuritis as an ophthalmologist? A United Kingdom perspective
  12. Applying a genetic risk score model to enhance prediction of future multiple sclerosis diagnosis at first presentation with optic neuritis
  13. Interpretation of composite OCT/MRI findings: a clinical review of retinotopy
  14. Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
  15. Partial Parallelism Plots
  16. Exploring Vitreous Haze as a Potential Biomarker for Accelerated Glymphatic Outflow and Neurodegeneration in Multiple Sclerosis: A Cross-Sectional Study
  17. Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial
  18. Correction: NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies
  19. NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies
  20. Reply: Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation
  21. Peripherin is a biomarker of axonal damage in peripheral nervous system disease
  22. The Association of Alcohol Consumption with Glaucoma and Related Traits
  23. Differentiating glaucoma from chiasmal compression using optical coherence tomography: the macular naso-temporal ratio
  24. Remodeling of the neuromuscular junction in myasthenia gravis increases serum neurofilament heavy chain levels
  25. Application of diagnostic criteria for optic neuritis – Authors' reply
  26. Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort
  27. Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders
  28. Correction: UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
  29. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
  30. Applying a genetic risk score model to enhance prediction of future Multiple Sclerosis diagnosis at first presentation with optic neuritis: a cohort study in the UK Biobank
  31. A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage
  32. Diagnosis and classification of optic neuritis
  33. The Role of the Inner Nuclear Layer for Perception of Persisting Tiling Inside a Monocular Scotoma
  34. UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
  35. Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort
  36. Pattern ERGs suggest a possible retinal contribution to the visual acuity loss in acute optic neuritis
  37. The 2022 Lady Estelle Wolfson lectureship on neurofilaments
  38. The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis
  39. Automated detection of hyperreflective foci in the outer nuclear layer of the retina
  40. The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts
  41. The prevalence of internuclear ophthalmoparesis in a population-based cohort of individuals with multiple sclerosis
  42. Artificial intelligence enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction and stroke
  43. Interpretation of Longitudinal Changes of the Inner Nuclear Layer in MS
  44. Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain
  45. Sub-cellular level resolution of common genetic variation in the photoreceptor layer identifies continuum between rare disease and common variation
  46. Associations of Alcohol Consumption and Smoking With Disease Risk and Neurodegeneration in Individuals With Multiple Sclerosis in the United Kingdom
  47. AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK
  48. Neuro-Ophthalmic Implications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Related Infection and Vaccination
  49. Blood GFAP as an emerging biomarker in brain and spinal cord disorders
  50. Upregulated Retinal Neurofilament Expression in Experimental Optic Neuritis
  51. Clinical review of retinotopy
  52. Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study
  53. Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
  54. Dynamic volume‐rendered optical coherence tomography pupillometry
  55. Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox
  56. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
  57. Myelin-oligodendrocyte glycoprotein antibody-associated disease
  58. Update on Optic Neuritis: An International View
  59. APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies
  60. Re-evaluating diabetic papillopathy using optical coherence tomography and inner retinal sublayer analysis
  61. Seven day pre-analytical stability of serum and plasma neurofilament light chain
  62. Artificial intelligence extension of the OSCAR‐IB criteria
  63. Three “Red Lines” for Pattern Recognition-Based Differential Diagnosis Using Optical Coherence Tomography in Clinical Practice
  64. Investigation of associations between retinal microvascular parameters and albuminuria in UK Biobank: a cross-sectional case-control study
  65. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries
  66. Peripapillary Hyper-reflective Ovoid Mass-like Structure (PHOMS): An Optical Coherence Tomography Marker of Axoplasmic Stasis in the Optic Nerve Head
  67. A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
  68. Reply to “Peripapillary Hyper‐Reflective Ovoid Masslike Structures in Astronauts”
  69. Relationships between retinal layer thickness and brain volumes in the UK Biobank cohort
  70. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
  71. Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain network
  72. Optical Coherence Tomography Angiography (OCTA) in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
  73. Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease
  74. Retinal asymmetry in multiple sclerosis
  75. Optical coherence tomography (OCT) in neuro-ophthalmology
  76. Serum neurofilament light chain withstands delayed freezing and repeated thawing
  77. Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis
  78. Comment on: Morphologic Features of Buried Optic Disc Drusen on En Face Optical Coherence Tomography and Optical Coherence Tomography Angiography
  79. Young Adults With Anterior Ischemic Optic Neuropathy: A Multicenter Optic Disc Drusen Study
  80. Multirater Validation of Peripapillary Hyperreflective Ovoid Mass-like Structures (PHOMS)
  81. Acute Disseminated Encephalomyelitis with Seizures and Myocarditis: A Fatal Triad
  82. Automated Pupillometry Using a Prototype Binocular Optical Coherence Tomography System
  83. Blocked Eye-Brain connection in Multiple Sclerosis
  84. Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank
  85. Biomarker Panel to Differentiate Brain Injury From Brain Dysfunction in Patients With Sepsis-Associated Encephalopathy
  86. Weighting evidence in MS: Obesity and neurodegeneration
  87. CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD
  88. Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives
  89. Genome-wide association meta-analysis of corneal curvature identifies novel loci and shared genetic influences across axial length and refractive error
  90. Anterior visual system imaging to investigate energy failure in multiple sclerosis
  91. Saccadic delay in multiple sclerosis: A quantitative description
  92. Can stability of visual fixation be a measure for disability in multiple sclerosis?
  93. Protein aggregate formation permits millennium-old brain preservation
  94. A conscious rethink: Why is brain tissue commonly preserved in the archaeological record? Commentary on: Petrone P, Pucci P, Niola M, et al. Heat-induced brain vitrification from the Vesuvius eruption in C.E. 79. N Engl J Med 2020;382:383-4. DOI: 10.10...
  95. Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort
  96. Associations with photoreceptor thickness measures in the UK Biobank
  97. Neuro-Ophthalmic Literature Review
  98. Multi-trait genome-wide association study identifies new loci associated with optic disc parameters
  99. Time is Vision
  100. Associations with Corneal Hysteresis in a Population Cohort
  101. A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients
  102. Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis
  103. Patterns of retrograde axonal degeneration in the visual system
  104. Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study
  105. Saccadic fatigability in the oculomotor system
  106. Progression of Anterograde Trans-Synaptic Degeneration in the Human Retina Is Modulated by Axonal Convergence and Divergence
  107. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up
  108. Diagnosing and quantifying a common deficit in multiple sclerosis
  109. Quantile regression analysis reveals widespread evidence for gene-environment or gene-gene interactions in myopia development
  110. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study
  111. Quantification of Visual Fixation in Multiple Sclerosis
  112. Correction: The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study
  113. A 30 s test for quantitative assessment of a relative afferent pupillary defect (RAPD): the infrared pupillary asymmetry (IPA)
  114. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
  115. The relevance of buffer system ionic strength in immunoassay development
  116. Cohort profile: design and methods in the eye and vision consortium of UK Biobank
  117. The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study
  118. An ontological foundation for ocular phenotypes and rare eye diseases
  119. Retinal Asymmetry in Multiple Sclerosis
  120. Peripapillary Hyperreflective Ovoid Mass-Like Structures
  121. The International Multiple Sclerosis Visual System Consortium
  122. Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline
  123. Peripapillary Ovoid Hyperreflectivity in Optic Disc Edema and Pseudopapilledema
  124. The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis
  125. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry
  126. Treating the Eyes to Help the Brain
  127. Neurofilaments as biomarkers in neurological disorders
  128. A standardized protocol for quantification of saccadic eye movements: DEMoNS
  129. Neuro-ophthalmic literature review
  130. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis
  131. Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error
  132. The Pulfrich phenomenon: Practical implications of the assessment of cases and effectiveness of treatment
  133. Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophy
  134. Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon
  135. Multicenter reliability of semiautomatic retinal layer segmentation using OCT
  136. Retinal optical coherence tomography shows optic disc changes in low intracranial pressure headaches: a case report
  137. Reply to the letter by Jasmin Zvorničanin on the article Prefoveal floaters as a differential diagnosis to optic neuritis: “mouches dormantes”
  138. Translational evidence for two distinct patterns of neuroaxonal injury in sepsis: a longitudinal, prospective translational study
  139. Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis
  140. The Optic Disc Drusen Studies Consortium Recommendations for Diagnosis of Optic Disc Drusen Using Optical Coherence Tomography
  141. Time is vision in recurrent optic neuritis
  142. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
  143. Biomarkers of Disease Progression
  144. Volume rendering of superficial optic disc drusen
  145. Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study
  146. Prefoveal floaters as a differential diagnosis to optic neuritis: “mouches dormantes”
  147. Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis
  148. Case 3-2017: A Man with Cardiac Sarcoidosis and New Diplopia and Weakness
  149. Optical coherence tomography angiography and retinal microvascular ramification in acute macular neuroretinopathy and paracentral acute middle maculopathy
  150. A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer
  151. Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
  152. Neuroprotection and visual function after optic neuritis
  153. Biomarkers in Neurodegenerative Diseases
  154. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis
  155. Retinal glymphatic system: an explanation for transient retinal layer volume changes?
  156. An early case of a natural barrier to axonal degeneration
  157. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study
  158. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies
  159. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study
  160. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study
  161. Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease
  162. Maintenance Intravenous Fluids in Acutely Ill Patients
  163. Autoimmunity in visual loss
  164. Elevated vitreous body glial fibrillary acidic protein in retinal diseases
  165. The prevalence of microcystic macular changes on optical coherence tomography of the macular region in optic nerve atrophy of non-neuritis origin: a prospective study
  166. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
  167. Cerebral Salt Wasting Syndrome
  168. Pain in Optic Perineuritis: Author Response
  169. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease
  170. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up
  171. Neuro-Ophthalmic Literature Review
  172. Diagnostic clues and manifesting carriers in fukutin-related protein (FKRP) limb-girdle muscular dystrophy
  173. The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid
  174. Visual pathway neurodegeneration winged by mitochondrial dysfunction
  175. Re: Garcia-Martin et al.: Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography (Ophthalmology 2014;121:573–9)
  176. Distribution of Retinal Layer Atrophy in Patients With Parkinson Disease and Association With Disease Severity and Duration
  177. Neuro-Ophthalmic Literature Review
  178. Physiological variation of retinal layer thickness is not caused by hydration: A randomised trial
  179. Retinal Segmentation to Demonstrate Hyperplasia in Ataxia of Charlevoix-Saguenay: Critique on Study Methodology and Results
  180. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
  181. The investigation of acute optic neuritis: a review and proposed protocol
  182. Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
  183. Serum lactate as a novel potential biomarker in multiple sclerosis
  184. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis
  185. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria
  186. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
  187. Neuro-Ophthalmic Literature Review
  188. Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis
  189. Diagnosis and classification of autoimmune optic neuropathy
  190. Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis
  191. Neurofilament heavy chain as a marker of neuroaxonal pathology and prognosis in acute encephalitis
  192. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
  193. Neuro-Ophthalmic Literature Review
  194. Recurrent Optic Perineuritis after Intranasal Cocaine Abuse
  195. Biomarker time out
  196. The Clinical Spectrum of Microcystic Macular Edema
  197. Distribution of Retinal Layer Atrophy in Patients With Parkinson Disease and Association With Disease Severity and Duration
  198. A dam for retrograde axonal degeneration in multiple sclerosis?
  199. Disease course heterogeneity and OCT in multiple sclerosis
  200. Retinal hyperaemia-related blood vessel artifacts are relevant to automated OCT layer segmentation
  201. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study
  202. Neurodegeneration and Multiple Sclerosis
  203. Optical Coherence Tomography to Assess Neurodegeneration in Multiple Sclerosis
  204. Optic Neuritis: Another Dickensian Diagnosis
  205. Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids and Fatal B-Cell Lymphoma—Reply
  206. Physiological variation of segmented OCT retinal layer thicknesses is short-lasting
  207. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
  208. Should CLIPPERS Be Considered a Prelymphoma State or a New Inflammatory Disease?—Reply
  209. Intrathecal oligoclonal IgG synthesis in multiple sclerosis
  210. Pain Management in Neurocritical Care
  211. Fatal B-cell Lymphoma Following Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids
  212. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis
  213. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome
  214. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported
  215. Influence of the Eye-Tracking–Based Follow-Up Function in Retinal Nerve Fiber Layer Thickness Using Fourier-Domain Optical Coherence Tomography
  216. Patterns of non-embolic transient monocular visual field loss
  217. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis
  218. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis
  219. Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?
  220. Embolic and Nonembolic Transient Monocular Visual Field Loss: A Clinicopathologic Review
  221. A Simple Sign for Recognizing Off–Axis OCT Measurement Beam Placement in the Context of Multicentre Studies
  222. Microcystic macular oedema in MS: T2 lesion or black hole?
  223. Comment on "Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model"
  224. Microcystic macular oedema confirmed, but not specific for multiple sclerosis
  225. Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1G93A Mice that Model ALS
  226. Recurrent Laughter-induced Syncope
  227. Biomarkers of Disease Progression
  228. Serum GFAP levels in optic neuropathies
  229. Glial S100B is elevated in serum across the spectrum of west nile virus infection
  230. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment
  231. Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury
  232. The Physiological Variation of the Retinal Nerve Fiber Layer Thickness and Macular Volume in Humans as Assessed by Spectral Domain–Optical Coherence Tomography
  233. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
  234. The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies
  235. Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest
  236. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis
  237. Axonal damage in the making: Neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter
  238. Cerebrospinal Fluid Ferritin Level, a Sensitive Diagnostic Test in Late-Presenting Subarachnoid Hemorrhage
  239. The Prognostic Value of Brain Extracellular Fluid Nitric Oxide Metabolites After Traumatic Brain Injury
  240. Erratum to: Rostrocaudal Dynamics of CSF Biomarkers
  241. Disease-Specific Cerebrospinal Fluid Investigations
  242. The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
  243. Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis
  244. Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure
  245. Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign
  246. Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus
  247. Exceptional preservation of a prehistoric human brain from Heslington, Yorkshire, UK
  248. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease
  249. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency
  250. The neurofilament light chain is not stable in vitro
  251. Reply
  252. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases
  253. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
  254. Remote Ischemic Preconditioning Protects the Brain Against Injury After Hypothermic Circulatory Arrest
  255. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament “hook” effect
  256. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study
  257. International Issues: The EAYNT
  258. Neurodegeneration in MS and NMO: The Eye and the Blood
  259. Matrix Metalloproteinases in Myasthenia Gravis
  260. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies
  261. Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
  262. Rostrocaudal Dynamics of CSF Biomarkers
  263. Evidence for acute neurotoxicity after chemotherapy
  264. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency
  265. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration
  266. PONM06 Plasma neurofilament heavy chain levels as a disease biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis
  267. Ocular Flutter Following Adenoviral Conjunctivitis in an Adult
  268. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis
  269. Anti-Heat Shock Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome
  270. Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases
  271. Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis
  272. Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes
  273. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels
  274. Liquordiagnostik bei CT-negativer Subarachnoidalblutung
  275. Cerebrospinal fluid ATP metabolites in multiple sclerosis
  276. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein
  277. Recurrent ptosis due to myopathy of the levator palpebrae superioris
  278. Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking
  279. Neurology training around the world: asking the trainees
  280. Neurofilament ELISA validation
  281. Short commentary on ‘a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking’
  282. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis
  283. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
  284. Synchronised Paroxysmal Ocular Tilt Reaction and Limb Dystonia
  285. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile Virus infection
  286. Synchronised Paroxysmal Ocular Tilt Reaction and Limb Dystonia
  287. A novel biomarker for retinal degeneration: vitreous body neurofilament proteins
  288. Cerebrospinal fluid biomarkers in multiple sclerosis
  289. The Longitudinal Profile of Bilirubin and Ferritin in the Cerebrospinal Fluid Following a Subarachnoid Hemorrhage: Diagnostic Implications
  290. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients
  291. The longitudinal profile of CSF markers during external lumbar drainage
  292. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome
  293. Improving the recovery of S100B protein in cerebral microdialysis: Implications for multimodal monitoring in neurocritical care
  294. EFNS guidelines on disease-specific CSF investigations
  295. The Value of the Serum Neurofilament Protein Heavy Chain as a Biomarker for Peri-operative Brain Injury After Carotid Endarterectomy
  296. Glial fibrillary acidic protein in Guillain-Barré syndrome: Methodological issues
  297. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
  298. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy
  299. The Historical Origin of the Pulfrich Effect: A Serendipitous Astronomic Observation at the Border of the Milky Way
  300. Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?
  301. Isolated, relapsing and progressive demyelinating diseases of the central nervous system
  302. Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology
  303. Glial and Axonal Body Fluid Biomarkers Are Related to Infarct Volume, Severity, and Outcome
  304. Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study
  305. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis
  306. Marathon related death due to brainstem herniation in rehydration-related hyponatraemia: a case report
  307. Assessing visual fields for driving in patients with paracentral scotomata
  308. CSF biomarkers for improved prognostic accuracy in acute CNS disease
  309. Plasma neurofilament heavy chain levels in Huntington's disease
  310. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis
  311. High CSF neurofilament heavy chain levels in neuromyelitis optica
  312. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain
  313. CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls
  314. A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia
  315. H<sub>2</sub>O Coma
  316. Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients
  317. CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndrome
  318. Brain Extracellular Fluid Nitrite/Nitrate Levels after Traumatic Brain Injury are Related to Survival
  319. Early Identification of Secondary Brain Damage in Subarachnoid Hemorrhage: A Role for Glial Fibrillary Acidic Protein
  320. Axonal damage and outcome in subarachnoid haemorrhage
  321. The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
  322. Clinical disorders affecting mesopic vision
  323. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis
  324. Intra-arterial papaverine used to treat cerebral vasospasm reduces brain oxygen
  325. Axonal damage markers in cerebrospinal fluid are increased in ALS
  326. Measurement of high affinity antibodies on antigen-immunoblots
  327. High Intracranial Pressure, Brain Herniation and Death in Cerebral Venous Thrombosis
  328. Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes
  329. Free phenytoin concentration measurement in brain extracellular fluid: a pilot study
  330. The Neurofilament Heavy Chain (NfH<sup>SMI35</sup>) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease
  331. Educational Approach on Stroke Training in Europe
  332. Spectrophotometry for Cerebrospinal Fluid Pigment Analysis
  333. Extracellular N‐acetylaspartate depletion in traumatic brain injury
  334. Amniotic fluid brain‐specific proteins are biomarkers for spinal cord injury in experimental myelomeningocele
  335. 4-Dihydromethyltrisporate dehydrogenase, an enzyme of the sex hormone pathway in Mucor mucedo, is constitutively transcribed but its activity is differently regulated in (+) and (−) mating types
  336. Optic flow induced nystagmus
  337. No evidence for MSRV viraemia and glial cell death in acute optic neuritis
  338. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
  339. Critical Illness Brain Syndrome (CIBS): An Underestimated Entity?
  340. Why Human Color Vision Cannot Reliably Detect Cerebrospinal Fluid Xanthochromia
  341. Extracellular fluid S100B in the injured brain: a future surrogate marker of acute brain injury?
  342. The Bryan cervical disc prosthesis as an alternative to arthrodesis in the treatment of cervical spondylosis: 46 CONSECUTIVE CASES
  343. Decreased CSF hypocretin-1 (orexin-A) after acute haemorrhagic brain injury
  344. Axonal Pathology in Subarachnoid and Intracerebral Hemorrhage
  345. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
  346. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis
  347. Central and Paracentral Visual Field Defects and Driving Abilities
  348. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis
  349. Spectrophotometry for Xanthochromia
  350. Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
  351. Axonal degeneration and inflammation in acute optic neuritis
  352. Transient monocular blindness: the controversial role of the ophthalmic artery
  353. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis
  354. Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage
  355. An ELISA for glial fibrillary acidic protein
  356. Temporal Alterations in Cerebrospinal Fluid Amyloid  -Protein and Apolipoprotein E After Subarachnoid Hemorrhage
  357. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage
  358. Alterations in Cerebrospinal Fluid Apolipoprotein E and Amyloid β -Protein after Traumatic Brain Injury
  359. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission
  360. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern
  361. A specific ELISA for measuring neurofilament heavy chain phosphoforms
  362. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
  363. Cerebrospinal fluid nitrite/nitrate predicts poor outcome in patients with subarachnoid hemorrhage (SAH)
  364. Quantification of neurodegeneration by measurement of brain-specific proteins
  365. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors
  366. Video Reconstruction of Vasospastic Transient Monocular Blindness
  367. Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury
  368. Cerebrospinal Fluid Apolipoprotein E Concentration Decreases after Traumatic Brain Injury
  369. Decreased Cerebrospinal Fluid Apolipoprotein E After Subarachnoid Hemorrhage: Correlation With Injury Severity and Clinical Outcome
  370. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy
  371. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease
  372. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: A pilot study
  373. Media Watch
  374. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations
  375. Rapidly developing intimal fibrosis mimicking giant cell arteritis
  376. Dense Kayser-Fleischer ring in asymptomatic Wilson's disease (hepatolenticular degeneration)
  377. Relapsing intracranial Rosai-Dorfman disease
  378. Recurrent ptosis
  379. Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat
  380. Recurrent ptosis in an adult due to isolated paresis of the levator palpebrae superioris and M�ller?s muscle of unknown aetiology
  381. Repetitive cerebral bleeding in an adult with Klippel-Trénaunay Syndrome
  382. Failure to detect bitemporal field defects due to chiasmal compression on a screening perimetry protocol
  383. Reply
  384. Hue memory and discrimination in young children
  385. Biological Markers
  386. Neuronal Cell Death and Axonal Degeneration: Neurofilaments as Biomarkers